PRMT5, A NOVEL EPIGENETIC TARGET IN LUNG CANCERS

被引：0

作者：

Otterson, Gregory A. ^{[1
]}

Wu, Xin ^{[1
]}

Welliver, Meng ^{[2
]}

Sharma, Smita ^{[2
]}

Shilo, Konstantin ^{[3
]}

机构：

[1] Ohio State Univ, Div Med Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] Ohio State Univ, Canc Ctr, Columbus, OH 43210 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

PRMT5; epigenetics;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.02-016

引用

页码：S757 / S758

页数：2

共 50 条

[21] PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
Welliver, Meng
Jin, Feng
Otterson, Gregory
Carbone, David
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S844
[22] PRMT5: a putative oncogene and therapeutic target in prostate cancer
Elena Beketova
Jake L. Owens
Andrew M. Asberry
Chang-Deng Hu
Cancer Gene Therapy, 2022, 29 : 264 - 276
[23] Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP deleted cancers
Bartosik, A.
Radzimierski, A.
Levenets, O.
Bobowska, A.
Stachowicz, A.
Kus, K.
Michalik, K.
Banaszak, K.
Krzemien, D.
Madej, M.
Skoda, M.
Tomczyk, I.
Podkalicka, P.
Gluza, K.
Satala, G.
Gondela, A.
Sowinska, M.
Boutard, N.
Brzozka, K.
Nowak, M.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S15 - S16
[24] Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutics for MTAP deleted cancers
Levenets, Oleksandr
Bartosik, Anna
Sowinska, Marta
Zuchowicz, Karol
Sasmal, Sujit
Korta-Piatek, Klara
Radzimierski, Adam
Niedziejko, Paulina
Popika, Oleksandr
Swirski, Mateusz
Stachowicz, Agata
Mikulski, Maciej
Sieprawska-Lupa, Magdalena
Banaszak, Katarzyna
Michalik, Kinga
Kus, Kamil
Madej, Monika
Podkowa, Adrian
Gluza, Karolina
Satala, Grzegorz
Cieluch, Ewelina
Krzemien, Dobroslawa
Gondela, Andrzej
Cwiertnia, Grzegorz
Wronowski, Marek
Boutard, Nicolas
Wieckowska, Aleksandra
Zezula, Joanna
Jablonska, Justyna
Gladysz, Miroslawa
Tomczyk, Igor
Faber, Jacek
Serocki, Marcin
Drwal, Eliza
Kozlowska-Tomczyk, Kamila
Skoda, Marta
Swarbrick, Martin
Brzozka, Krzysztof
Nowak, Mateusz
CANCER RESEARCH, 2022, 82 (12)
[25] PRMT5 Regulates DNA Repair By Controlling the Alternative Splicing of Epigenetic Factors
Hamard, Pierre-Jacques
Santiago, Gabriel Emmanuel
Liu, Fan
Greenblatt, Sarah
Karl, Daniel
Martinez, Concepcion
Verdun, Ramiro E.
Nimer, Stephen D.
BLOOD, 2017, 130
[26] A new move for PRMT5
Joanna E. Huddleston
Nature Reviews Molecular Cell Biology, 2011, 12 : 76 - 76
[27] PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Kumar, Devendra
Jain, Stuti
Coulter, Don W.
Joshi, Shantaram S.
Chaturvedi, Nagendra K.
CANCERS, 2023, 15 (24)
[28] PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia
Hing, Zachary A.
Skinner, Jordan N.
Beaver, Larry P.
Lai, Tzung-Huei
Cempre, Casey B.
Harrington, Bonnie K.
Sampath, Deepa
Lehman, Amy M.
Yu, Lianbo
Alinari, Lapo
Byrd, John C.
Baiocchi, Robert A.
Lapalombella, Rosa
BLOOD, 2017, 130
[29] The Where and the How of PRMT5
Cheryl M. Koh
Marco Bezzi
Ernesto Guccione
Current Molecular Biology Reports, 2015, 1 (1) : 19 - 28
[30] A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models
Brehmer, Dirk
Wu, Tongfei
Mannens, Geert
Beke, Lijs
Vinken, Petra
Gaffney, Dana
Sun, Weimei
Pande, Vineet
Thuring, Jan-Willem
Millar, Hillary
Poggesi, Italo
Somers, Ivan
Boeckx, An
Parade, Marc
van Heerde, Erika
Nys, Thomas
Yanovich, Carol
Herkert, Barbara
Verhulst, Tinne
Du Jardin, Marc
Meerpoel, Lieven
Moy, Christopher
Diels, Gaston
Viellevoye, Marcel
Schepens, Wim
Poncelet, Alain
Linders, Joannes T.
Lawson, Edward C.
Edwards, James P.
Chetty, Dushen
Laquerre, Sylvie
Lorenzi, Matthew V.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →